Our pipeline
Advancing a New Generation of Neuropsychiatric Treatments
DT-101
Major Depressive Disorder (MDD)
DT-101 is a next-generation AMPA receptor positive allosteric modulator designed to restore synaptic connectivity in MDD. It offers a high therapeutic index, enabling effective receptor modulation while maintaining a favourable safety and tolerability profile. DT-101 is intended to deliver rapid and robust antidepressant effects, with potential benefits on cognitive impairment.
DT-201
Neuropsychiatry (undisclosed)
DT-201 is a novel, highly selective negative allosteric modulator (NAM) of the α5-GABAA receptor subtype, with minimal activity at other receptor subtypes. It is designed to deliver best-in-class potency and offers broad therapeutic potential across several neuropsychiatric disorders.
DT-301
Neuropsychiatry (undisclosed)
DT-301 is a novel, highly selective positive allosteric modulator (PAM) of the α2/α3-GABAA receptor subtypes, with best-in-class selectivity, designed to deliver a leading safety and tolerability profile.
By avoiding activity at α1 and α5 GABAA receptors – subtypes associated with sedation, and cognitive impairment, respectively – DT-301 is intended to provide robust therapeutic benefit while minimising limiting side effects. This profile supports its broad potential across a range of neuropsychiatric disorders, including in vulnerable and elderly populations.
DT-101
DT-101 is a next-generation AMPA receptor positive allosteric modulator designed to restore synaptic connectivity in MDD. It offers a high therapeutic index, enabling effective receptor modulation while maintaining a favourable safety and tolerability profile. DT-101 is intended to deliver rapid and robust antidepressant effects, with potential benefits on cognitive impairment.
Need in major depressive disorder
When Standard
Treatment Isn't Enough
More than 50% of patients fail to achieve remission with current treatments. Limitations include slow onset of action, suboptimal efficacy, cognitive impairment, and burdensome side effects such as sexual dysfunction, weight gain, and dissociation.
Our understanding of major depressive disorder (MDD) neurobiology is evolving and it is increasingly being understood as a disorder of disrupted synaptic connectivity. Chronic stress alters the balance between excitatory and inhibitory signaling, leading to reduced synaptic plasticity and network dysfunction. Many existing therapies do not adequately address this underlying biology.
Why AMPA Receptors?
AMPA receptors are central regulators of mood, synaptic plasticity, and cognitive function. Growing evidence supports AMPA receptor modulation as a clinically validated approach, with antidepressant effects observed in both preclinical and clinical settings. Converging data also position AMPA receptor activity as a key downstream driver of effective therapies that enhance synaptic plasticity, such as esketamine.
TARIAN-1:
Phase 2 Clinical Trial
TARIAN-1 is a global, randomised, double-blind, placebo-controlled, Phase 2 trial evaluating the efficacy, safety, and tolerability of DT-101 in people with MDD. The trial has been initiated in the U.S., with further initiations planned in the U.K. and EU in 2026. TARIAN-1 is evaluating DT-101 compared to placebo with change in participants’ Montgomery Åsberg depression rating scale (MADRS) score as the primary endpoint. The trial aims to enrol more than 300 participants. TARIAN is the Welsh word for “shield,” reflecting the underlying objective of the trial – to protect individuals from the debilitating effects of depression.
The Future of Brain Health Starts Here
Whether you're a patient, caregiver, researcher, investor, or member of the press, we'd love to hear from you.
